258
- Xiao X, Chang C. Diagnosis and classification of drug-induced autoimmunity (DIA).
J Autoimmun. 2014;48-49:66–72. - Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor
alpha agents. Semin Arthritis Rheum. 2008;37(6):381–7. - Vaz JL, et al. Infliximab-induced autoantibodies: a multicenter study. Clin Rheumatol.
2016;35(2):325–32. - Nancey S, et al. Infliximab treatment does not induce organ-specific or nonorgan-specific
autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in
Crohn’s disease. Inflamm Bowel Dis. 2005;11(11):986–91. - Wetter DA, Davis MD. Lupus-like syndrome attributable to anti-tumor necrosis fac-
tor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc.
2009;84(11):979–84. - Williams VL, Cohen PR. TNF alpha antagonist-induced lupus-like syndrome: report and
review of the literature with implications for treatment with alternative TNF alpha antago-
nists. Int J Dermatol. 2011;50(5):619–25. - Amarante CF, et al. Drug-induced lupus with leukocytoclastic vasculitis: a rare expression
associated with adalimumab. An Bras Dermatol. 2015;90(3 Suppl 1):121–4. - Moulis G, et al. Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syn-
drome the same with monoclonal antibodies and soluble receptor? A case/non-case study in
a nationwide pharmacovigilance database. Rheumatology (Oxford). 2014;53(10):1864–71. - Boodhoo KD, Liu S, Zuo X. Impact of sex disparities on the clinical manifestations in
patients with systemic lupus erythematosus: a systematic review and meta-analysis. Medicine
(Baltimore). 2016;95(29):e4272. - Yacoub Wasef SZ. Gender differences in systemic lupus erythematosus. Gend Med.
2004;1(1):12–7. - Das J, et al. Endogenous humoral autoreactive immune responses to apoptotic cells:
effects on phagocytic uptake, chemotactic migration and antigenic spread. Eur J Immunol.
2008;38(12):3561–74. - D'Auria F, et al. Accumulation of plasma nucleosomes upon treatment with anti-tumour
necrosis factor-alpha antibodies. J Intern Med. 2004;255(3):409–18. - Kocharla L, Mongey AB. Is the development of drug-related lupus a contraindication for
switching from one TNF alpha inhibitor to another? Lupus. 2009;18(2):169–71. - Shelton E, et al. New onset idiosyncratic liver enzyme elevations with biological therapy in
inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41(10):972–9. - Rodrigues S, et al. Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: a
single center report of 8 cases. World J Gastroenterol. 2015;21(24):7584–8. - Ghabril M, et al. Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-
four cases. Clin Gastroenterol Hepatol. 2013;11(5):558–564.e3. - Bjornsson ES, et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists.
Clin Gastroenterol Hepatol. 2015;13(3):602–8. - Thiefin G, et al. Infliximab-induced hepatitis: absence of cross-toxicity with etanercept. Joint
Bone Spine. 2008;75(6):737–9. - Massarotti M, Marasini B. Successful treatment with etanercept of a patient with pso-
riatic arthritis after adalimumab-related hepatotoxicity. Int J Immunopathol Pharmacol.
2009;22(2):547–9. - Garcia Aparicio AM, et al. Successful treatment with etanercept in a patient with hepatotoxic-
ity closely related to infliximab. Clin Rheumatol. 2007;26(5):811–3. - Becker H, et al. Etanercept tolerance in a patient with previous infliximab-induced hepatitis.
Clin Rheumatol. 2008;27(12):1597–8. - Cheng FK, Bridges EE, Betteridge JD. Drug-induced liver injury from initial dose of inflix-
imab. Mil Med. 2015;180(6):e723–4. - Tobon GJ, et al. Serious liver disease induced by infliximab. Clin Rheumatol.
2007;26(4):578–81.
U. Wong and R.K. Cross